← Back to All US Stocks

PepGen Inc. (PEPG) Fundamental Analysis & AI Grade 2026

PEPG Nasdaq Pharmaceutical Preparations DE CIK: 0001835597
Updated This Month • Analysis: May 16, 2026 • SEC Data: 2026-03-31
Combined AI Grade
C
68% Confidence
N/A
C
68% Conf
Pending
Analysis scheduled

📊 PEPG Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: $-18.4M
Current Ratio: 14.98x
Debt/Equity: 0.00x
EPS: $-0.26
AI Grade: C with 68% confidence
PepGen Inc. (PEPG) receives a C fundamental grade with 68% confidence from our AI analysis based on SEC 10-K filings., and return on equity (ROE) of -13.3% Below is our complete PEPG stock analysis for 2026.

Is PepGen Inc. (PEPG) a Good Investment?

Claude

PepGen is a pre-revenue pharmaceutical company burning approximately $18.4M annually with no clear path to profitability. Despite a solid balance sheet with zero debt and $42.1M in cash (providing ~2+ years runway), the absence of revenue generation, persistent operating losses, and typical biotech execution risk present material downside. The modest improvement in loss trajectory is insufficient to offset the fundamental lack of commercial traction.

PepGen Inc. Key Strengths (PEPG)

Claude
  • + Strong balance sheet with zero debt and $134M stockholders' equity
  • + Excellent liquidity position with 14.98x current ratio and $42.1M cash reserves
  • + Improving loss profile with 25.6% YoY improvement in diluted EPS

PEPG Stock Risks: PepGen Inc. Investment Risks

Claude
  • ! No revenue generation indicating pre-commercial stage with high development risk
  • ! Significant operating cash burn of $18.4M annually with limited profitability visibility
  • ! Typical biotech execution and pipeline risk with uncertain clinical success rates
  • ! Constrained cash runway despite adequate current position without revenue inflection

Key Metrics to Watch

Claude
  • * Operating cash burn rate and remaining cash runway
  • * Clinical development milestones and regulatory approval progress
  • * Timeline to first commercial revenue and addressable market size
  • * Insider trading activity frequency and transaction direction

PepGen Inc. (PEPG) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
$-17.8M
EPS (Diluted)
$-0.26
Free Cash Flow
$-18.4M
Total Assets
$156.3M
Cash Position
$42.2M

💡 AI Analyst Insight

Strong liquidity with a 14.98x current ratio provides a solid financial cushion.

PEPG Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -13.3%
ROA -11.4%
FCF Margin N/A

PEPG vs Healthcare Sector: How PepGen Inc. Compares

How PepGen Inc. compares to Healthcare sector averages

Net Margin
PEPG 0.0%
vs
Sector Avg 12.0%
PEPG Sector
ROE
PEPG -13.3%
vs
Sector Avg 15.0%
PEPG Sector
Current Ratio
PEPG 15.0x
vs
Sector Avg 2.0x
PEPG Sector
Debt/Equity
PEPG 0.0x
vs
Sector Avg 0.6x
PEPG Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is PepGen Inc. Stock Overvalued? PEPG Valuation Analysis 2026

Based on fundamental analysis, PepGen Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-13.3%
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

PepGen Inc. Balance Sheet: PEPG Debt, Cash & Liquidity

Current Ratio
14.98x
Quick Ratio
14.98x
Debt/Equity
0.00x
Debt/Assets
14.3%
Interest Coverage
N/A
Long-term Debt
N/A

PEPG Revenue & Earnings Growth: 5-Year Financial Trend

PEPG 5-year financial data:
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: PepGen Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.85 indicates the company is currently unprofitable.

PEPG Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

PepGen Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$18.4M
Cash generated from operations
Dividends
None
No dividend program

PEPG SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for PepGen Inc. (CIK: 0001835597)

📋 Recent SEC Filings

Date Form Document Action
May 26, 2026 4 xslF345X06/ownership.xml View →
May 21, 2026 8-K d54577d8k.htm View →
May 12, 2026 8-K pepg-20260512.htm View →
May 12, 2026 10-Q pepg-20260331.htm View →
Apr 28, 2026 DEF 14A pepg-20260428.htm View →

Frequently Asked Questions about PEPG

What is the AI rating for PEPG?

PepGen Inc. (PEPG) has an AI grade of C with 68% confidence, based on fundamental analysis of SEC EDGAR filings.

What are PEPG's key strengths?

Claude: Strong balance sheet with zero debt and $134M stockholders' equity. Excellent liquidity position with 14.98x current ratio and $42.1M cash reserves.

What are the risks of investing in PEPG?

Claude: No revenue generation indicating pre-commercial stage with high development risk. Significant operating cash burn of $18.4M annually with limited profitability visibility.

What is PEPG's revenue and growth?

PepGen Inc. reported revenue of N/A.

Does PEPG pay dividends?

PepGen Inc. does not currently pay dividends.

Where can I find PEPG SEC filings?

Official SEC filings for PepGen Inc. (CIK: 0001835597) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is PEPG's EPS?

PepGen Inc. has a diluted EPS of $-0.26.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is PEPG's fundamental grade?

Based on our AI fundamental analysis in May 2026, PepGen Inc. has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is PEPG stock overvalued or undervalued?

Valuation metrics for PEPG: ROE of -13.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is PEPG's AI grade for 2026?

Our dual AI analysis gives PepGen Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is PEPG's free cash flow?

PepGen Inc.'s operating cash flow is $-18.4M, with capital expenditures of $0.0.

How does PEPG compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.3% (avg: 15%), current ratio 14.98 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 16, 2026 | Data as of: 2026-03-31 | Powered by Claude AI